Metactive Presents Results from Nonclinical Research Study Treating Carotid Artery Aneurysms

FAIRWAY, Kan.--()--Metactive Medical Inc. (Metactive), a medical device company developing innovative products for the treatment of neurovascular and peripheral vascular diseases, announced today that Dr. Kieran Murphy, Professor, Vice Chair, and Director of Research in the Department of Medical Imaging at the University of Toronto, presented new nonclinical results from Metactive’s neurovascular research program at the Society of Interventional Radiology (SIR) Annual Scientific Meeting.

In an oral presentation titled “Treatment of Carotid Artery Terminal Bifurcation, Complex Bifurcation and Sidewall Aneurysms in Canines with the Ballstent Microcatheter”, Dr. Murphy discussed results from the treatment of ten aneurysms with the Ballstent Microcatheter™ in well-accepted nonclinical models of cerebral aneurysm. Six large, narrow and wide-necked terminal carotid artery bifurcation aneurysms, two large, wide-necked complex carotid artery bifurcation aneurysms, and two wide-necked carotid artery sidewall aneurysms were each treated with a Ballstent and coils. One narrow-necked terminal carotid artery bifurcation aneurysm was treated with a Ballstent only.

At 4 - 12-week follow-up, nine aneurysms demonstrated 100% aneurysm neck and sac occlusion by histology. The remaining aneurysm demonstrated 95% occlusion, with recanalization of a small segment of the aneurysm neck that had been treated with a single coil during a follow-up procedure. All aneurysms demonstrated rapid and complete or near-complete endothelialization of the aneurysm neck, a critical requirement for an effective and durable treatment of saccular aneurysms. An additional large, narrow-necked terminal carotid artery bifurcation aneurysm was treated with 17 commercially available coils alone. This aneurysm did not show complete occlusion by angiography immediately after treatment or at four weeks, and histology demonstrated only 67% aneurysm neck occlusion with recanalization channels extending into the aneurysm sac.

In this nonclinical study, the Ballstent Microcatheter, when used with a few coils, delivered rapid and complete occlusion of the neck and sac of a wide range of aneurysm sizes, shapes and configurations, including hard to treat large, wide-necked bifurcation and terminal aneurysms,” said Dr. Murphy. “The study also showed good biocompatibility for the Ballstent and rapid endothelialization of the aneurysm neck after treatment. This new device has the potential to be useful for patients with large aneurysms, aneurysms arising from bifurcations, ruptured aneurysms, and aneurysms in patients who would benefit from avoiding long-term anticoagulation.”

The Society of Interventional Radiology (SIR) Annual Scientific Meeting was held March 17 - 22, 2018 in Los Angeles.

About Ballstent Microcatheter

The Ballstent Microcatheter is a novel saccular aneurysm embolization device comprising a 3.3 Fr, highly flexible .014” guidewire-compatible microcatheter delivery system and an inflatable, detachable, intrasaccular metallic balloon that can be used with coils to provide immediate, complete, and lasting aneurysm occlusion and rapid endothelialization of the aneurysm neck.

About Cerebral Aneurysm Embolization

More than 80,000 cerebral aneurysm embolization procedures are performed worldwide each year using coils, flow-diverting stents, intra-saccular devices, and liquid embolics. There is a need for cerebral aneurysm embolization devices that are highly flexible and deliverable, can be placed with a high degree of precision within the aneurysm sac, and provide immediate, complete, and lasting aneurysm neck and sac occlusion.

About Metactive Medical

Metactive is developing innovative new medical devices for the treatment of neurovascular and peripheral vascular diseases. Metactive's first products enable precise and immediate occlusion and rapid sealing of cerebral aneurysms, arteries, and veins using an over-the-wire microcatheter platform. For more information, please visit www.metactivemedical.com.

Contacts

Metactive Medical, Inc.
F. Nicholas Franano, MD, 816-550-9177
President and CEO
nfranano@metactivemedical.com
or
Media:
MacDougall Biomedical Communications
Kara Mazey, 781-235-3060
kmazey@macbiocom.com

Release Summary

Metactive Medical announces new nonclinical results from the company's neurovascular research program were presented at the SIR 2018 Scientific Meeting.

Contacts

Metactive Medical, Inc.
F. Nicholas Franano, MD, 816-550-9177
President and CEO
nfranano@metactivemedical.com
or
Media:
MacDougall Biomedical Communications
Kara Mazey, 781-235-3060
kmazey@macbiocom.com